# Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

> **NCT03622788** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Aplastic Anemia
- Bone Marrow Failure
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Follicular Lymphoma
- Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
- Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Anti-Thymocyte Globulin
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Cytokine-treated Veto Cells
- **DRUG:** Fludarabine
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **RADIATION:** Total-Body Irradiation

## Key facts

- **NCT ID:** NCT03622788
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-08
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03622788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03622788, "Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03622788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*